Literature DB >> 24386943

The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma.

Yasuhiro Oki1, Hubert Chuang, Beth Chasen, Aaron Jessop, Tinsu Pan, Michelle Fanale, Bouthaina Dabaja, Nathan Fowler, Jorge Romaguera, Luis Fayad, Fredrick Hagemeister, Maria Alma Rodriguez, Sattva Neelapu, Felipe Samaniego, Larry Kwak, Anas Younes.   

Abstract

The prognostic value of interim positron emission tomography (PET) was evaluated after 2 cycles of doxorubicin, bleomycin, vinblastin and dacarbazine in classical Hodgkin lymphoma patients (n = 229), based on Deauville criteria. In early stage non-bulky disease, bulky stage II disease, advanced stage low International Prognostic Score (IPS ≤2) and advanced stage (IPS ≥3), 3-year progression-free survival rates in PET2-negative vs. PET2-positive groups were 95·9% vs. 76·9% (P < 0·0018), 83·3% vs. 20·0% (P = 0·017), 77·0% vs. 30·0% (P < 0·001) and 71·0% vs. 44·4%(P = 0·155), respectively. The outcome after positive PET2 was better than previously reported. The results from non-randomized studies of PET2-guided therapy would be valuable with careful interpretation.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  Hodgkin lymphoma; positron emission tomography; prognostic

Mesh：

Year:  2014        PMID： 24386943      PMCID： PMC5308126          DOI： 10.1111/bjh.12715

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  10 in total

1.  18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.

Authors:  Juliano J Cerci; Luís F Pracchia; Camila C G Linardi; Felipe A Pitella; Dominique Delbeke; Marisa Izaki; Evelinda Trindade; José Soares; Valeria Buccheri; José C Meneghetti
Journal:  J Nucl Med       Date:  2010-08-18       Impact factor: 10.057

2.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

Authors:  Martin Hutchings; Annika Loft; Mads Hansen; Lars Møller Pedersen; Thora Buhl; Jesper Jurlander; Simon Buus; Susanne Keiding; Francesco D'Amore; Anne-Marie Boesen; Anne Kiil Berthelsen; Lena Specht
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

3.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

Authors:  Malik E Juweid; Sigrid Stroobants; Otto S Hoekstra; Felix M Mottaghy; Markus Dietlein; Ali Guermazi; Gregory A Wiseman; Lale Kostakoglu; Klemens Scheidhauer; Andreas Buck; Ralph Naumann; Karoline Spaepen; Rodney J Hicks; Wolfgang A Weber; Sven N Reske; Markus Schwaiger; Lawrence H Schwartz; Josee M Zijlstra; Barry A Siegel; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

4.  Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.

Authors:  Yousif Matloub; Susan Lindemulder; Paul S Gaynon; Harland Sather; Mei La; Emmett Broxson; Rochelle Yanofsky; Raymond Hutchinson; Nyla A Heerema; James Nachman; Marilyn Blake; Linda M Wells; April D Sorrell; Margaret Masterson; John F Kelleher; Linda C Stork
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

5.  Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria.

Authors:  Pierre-Yves Le Roux; Thomas Gastinne; Steven Le Gouill; Emmanuel Nowak; Caroline Bodet-Milin; Solène Querellou; Beatrice Mahe; Viviane Dubruille; Nicolas Blin; Pierre Yves Salaun; Françoise Bodere-Kraeber
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-10       Impact factor: 9.236

6.  Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients.

Authors:  Pier Luigi Zinzani; Luigi Rigacci; Vittorio Stefoni; Alessandro Broccoli; Benedetta Puccini; Antonio Castagnoli; Luca Vaggelli; Lucia Zanoni; Lisa Argnani; Michele Baccarani; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-06       Impact factor: 9.236

Review 7.  Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review.

Authors:  Teruhiko Terasawa; Joseph Lau; Stéphane Bardet; Olivier Couturier; Tomomitsu Hotta; Martin Hutchings; Takashi Nihashi; Hirokazu Nagai
Journal:  J Clin Oncol       Date:  2009-03-09       Impact factor: 44.544

8.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.

Authors:  Andrea Gallamini; Martin Hutchings; Luigi Rigacci; Lena Specht; Francesco Merli; Mads Hansen; Caterina Patti; Annika Loft; Francesco Di Raimondo; Francesco D'Amore; Alberto Biggi; Umberto Vitolo; Caterina Stelitano; Rosario Sancetta; Livio Trentin; Stefano Luminari; Emilio Iannitto; Simonetta Viviani; Ivana Pierri; Alessandro Levis
Journal:  J Clin Oncol       Date:  2007-07-23       Impact factor: 44.544

9.  Report on the First International Workshop on Interim-PET-Scan in Lymphoma.

Authors:  Michel Meignan; Andrea Gallamini; Michel Meignan; Andrea Gallamini; Corinne Haioun
Journal:  Leuk Lymphoma       Date:  2009-08

10.  International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.

Authors:  Alberto Biggi; Andrea Gallamini; Stephane Chauvie; Martin Hutchings; Lale Kostakoglu; Michele Gregianin; Michel Meignan; Bogdan Malkowski; Michael S Hofman; Sally F Barrington
Journal:  J Nucl Med       Date:  2013-03-20       Impact factor: 10.057
  10 in total
  14 in total

1.  FDG PET in response evaluation of bulky masses in paediatric Hodgkin's lymphoma (HL) patients enrolled in the Italian AIEOP-LH2004 trial.

Authors:  Egesta Lopci; Maurizio Mascarin; Arnoldo Piccardo; Angelo Castello; Caterina Elia; Luca Guerra; Eugenio Borsatti; Alessandra Sala; Alessandra Todesco; Pietro Zucchetta; Piero Farruggia; Angelina Cistaro; Salvatore Buffardi; Patrizia Bertolini; Maurizio Bianchi; Maria Luisa Moleti; Feisal Bunkheila; Paolo Indolfi; Franca Fagioli; Alberto Garaventa; Roberta Burnelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-15       Impact factor: 9.236

2.  Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?

Authors:  Sarah A Milgrom; Chelsea C Pinnix; Hubert Chuang; Yasuhiro Oki; Mani Akhtari; Osama Mawlawi; Naveen Garg; Jillian R Gunther; Jay P Reddy; Grace L Smith; Eric Rohren; Frederick B Hagemeister; Hun J Lee; Luis E Fayad; Wenli Dong; Eleanor M Osborne; Zeinab Abou Yehia; Michelle Fanale; Bouthaina S Dabaja
Journal:  Br J Haematol       Date:  2017-08-18       Impact factor: 6.998

3.  Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy.

Authors:  Neetha Gandikota; Sidonie Hartridge-Lambert; Jocelyn C Migliacci; Joachim Yahalom; Carol S Portlock; Heiko Schöder
Journal:  Cancer       Date:  2015-03-04       Impact factor: 6.860

4.  US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

Authors:  Oliver W Press; Hongli Li; Heiko Schöder; David J Straus; Craig H Moskowitz; Michael LeBlanc; Lisa M Rimsza; Nancy L Bartlett; Andrew M Evens; Erik S Mittra; Ann S LaCasce; John W Sweetenham; Paul M Barr; Michelle A Fanale; Michael V Knopp; Ariela Noy; Eric D Hsi; James R Cook; Mary Jo Lechowicz; Randy D Gascoyne; John P Leonard; Brad S Kahl; Bruce D Cheson; Richard I Fisher; Jonathan W Friedberg
Journal:  J Clin Oncol       Date:  2016-04-11       Impact factor: 44.544

5.  Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.

Authors:  Angela Aldin; Lisa Umlauff; Lise J Estcourt; Gary Collins; Karel Gm Moons; Andreas Engert; Carsten Kobe; Bastian von Tresckow; Madhuri Haque; Farid Foroutan; Nina Kreuzberger; Marialena Trivella; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2019-09-16

6.  Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.

Authors:  Angela Aldin; Lisa Umlauff; Lise J Estcourt; Gary Collins; Karel Gm Moons; Andreas Engert; Carsten Kobe; Bastian von Tresckow; Madhuri Haque; Farid Foroutan; Nina Kreuzberger; Marialena Trivella; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2020-01-13

7.  Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma.

Authors:  Deborah M Stephens; Hongli Li; Heiko Schöder; David J Straus; Craig H Moskowitz; Michael LeBlanc; Lisa M Rimsza; Nancy L Bartlett; Andrew M Evens; Ann S LaCasce; Paul M Barr; Michael V Knopp; Eric D Hsi; John P Leonard; Brad S Kahl; Sonali M Smith; Jonathan W Friedberg
Journal:  Blood       Date:  2019-10-10       Impact factor: 25.476

8.  Inter-Reader Reliability of Early FDG-PET/CT Response Assessment Using the Deauville Scale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin's Lymphoma.

Authors:  Regine Kluge; Lidia Chavdarova; Martha Hoffmann; Carsten Kobe; Bogdan Malkowski; Françoise Montravers; Lars Kurch; Thomas Georgi; Markus Dietlein; W Hamish Wallace; Jonas Karlen; Ana Fernández-Teijeiro; Michaela Cepelova; Lorrain Wilson; Eva Bergstraesser; Osama Sabri; Christine Mauz-Körholz; Dieter Körholz; Dirk Hasenclever
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

9.  Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial.

Authors:  Alexey V Danilov; Hongli Li; Oliver W Press; Ilan Shapira; Lode J Swinnen; Ariela Noy; Erin Reid; Sonali M Smith; Jonathan W Friedberg
Journal:  Leuk Lymphoma       Date:  2016-07-07

10.  The relation between staging fluorine-18 fluorodeoxyglucose positron emission tomog- raphy/computed tomography metabolic parameters and tumor necrosis rate in pediatric osteosarcoma patients

Authors:  Aykut Kürşat Fidan; Gülin Uçmak; Bedriye Büşra Demirel; Hülya Efetürk; İpek Öztürk; Semra Demirtaş Şenlik; Burcu Esen Akkaş; İnci Ergürhan İlhan
Journal:  Turk J Med Sci       Date:  2021-06-28       Impact factor: 0.973
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.